Anika Therapeutics, Inc. (NASDAQ:ANIK)

CAPS Rating: 3 out of 5

The Company develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair.

Results 1 - 20 of 42 : 1 2 3 Next »

Recs

0
Member Avatar healthcarevalue (97.73) Submitted: 3/31/2015 6:43:30 PM : Outperform Start Price: $41.18 ANIK Score: -21.05

ANIK - Anika Therapeutics Inc. - negligible to zero debt/equity ratio. Return on Invested Capital (ROIC) = 24.43 TTM. Price/earnings ratio of 16.4 TTM is reasonable. Niche biotech healthcare industry company specializing in therapeutic products for tissue repair and multiple different treatments in increasing demand by baby boomers.

Recs

0
Member Avatar Haugurafpeningum (28.63) Submitted: 3/16/2015 10:34:34 AM : Outperform Start Price: $40.13 ANIK Score: -18.26

Arie Goren

Recs

0
Member Avatar derbydog85 (27.75) Submitted: 3/14/2015 12:25:04 AM : Outperform Start Price: $39.97 ANIK Score: -18.40

Awesome chart of increasing profits. Solid well run company will be a buy for years to come.

Recs

0
Member Avatar puneetkataria (< 20) Submitted: 3/1/2015 1:47:37 AM : Outperform Start Price: $39.96 ANIK Score: -16.38

Great fundamentals and a huge market for the products.

Recs

1
Member Avatar Kenji94 (62.35) Submitted: 8/29/2014 1:51:14 AM : Outperform Start Price: $41.90 ANIK Score: -25.53

Very good fundamentals

Recs

0
Member Avatar AnsgarJohn (99.34) Submitted: 8/26/2014 6:47:52 PM : Outperform Start Price: $41.78 ANIK Score: -25.31

Validea top 5 Gurus. I'm clueless. Peter Lynch value $58

Recs

1
Member Avatar TMFBuild (44.20) Submitted: 7/8/2014 3:22:33 PM : Outperform Start Price: $47.77 ANIK Score: -37.72

The company is into development and manufacturing of therapeutics products for tissue protection, healing, and repair in the United States, Europe, and internationally.
- Deals with chronic and relevant diseases
- Pipeline of New drugs pending approval
- Profit margin 35%
- No debt
- Can venture into new geographical locations through partnerships

Recs

1
Member Avatar staylo2561 (25.79) Submitted: 3/11/2014 10:37:04 AM : Outperform Start Price: $42.57 ANIK Score: -33.68

The new approved drug is based on HRA, and is a one injection shot to the knee for osteoarthritis. I have taken HRA for years....It is a miracle drug.

Recs

0
Member Avatar TerryFool (75.87) Submitted: 3/1/2014 11:05:20 AM : Outperform Start Price: $38.79 ANIK Score: -28.10

BP $39, long term buy, PEG .88

Recs

0
Member Avatar 1badbeerad (33.01) Submitted: 7/17/2013 3:07:58 PM : Outperform Start Price: $19.87 ANIK Score: +44.14

Rocket man

Recs

0
Member Avatar TerryHoodSr (77.87) Submitted: 5/27/2013 3:30:28 PM : Outperform Start Price: $30.90 ANIK Score: -10.56

3 YR EPS growth 39%

Recs

0
Member Avatar chris293 (82.42) Submitted: 4/9/2013 10:41:10 PM : Outperform Start Price: $13.72 ANIK Score: +111.46

Putting skin over metal, wasn't that a movie? Really, skin is the body's biggest organ and the need for this medical product of replacement skin
for injuries from any number of causes is great.

Recs

0
Member Avatar Winnerfrommidlan (53.49) Submitted: 4/15/2012 4:14:17 PM : Outperform Start Price: $16.12 ANIK Score: +55.59

Sales and earnings growth is accelerating.

Recs

4
Member Avatar depletemycapital (< 20) Submitted: 3/9/2012 5:01:14 PM : Outperform Start Price: $11.90 ANIK Score: +129.91

okay 1 year later, now year # 5 of my original purchase of ANIK. I finally believe this company has turned the corner. The beating for the stock not staying above $12 was due to the FDA not wanting to give them quick track approval for Monovisc. This is a single injection viscosupplement. It's alreadry approved & sold widely in Europe.

Now, the FDA has all of a sudden slowed the process down, that's for all companies. But Anik is seeking the help of J&J, whose subsidiary Depuy Mitek markets orthovisc ( 3 injections) to help with FDA approval. But the critical point is that management got rid of all the useless agendas of elevess ( or whatever it's called now) & focused on it's core product. Their market share stands @ 14% & growing. Secondly, the Anika s.r.l, their italian subsidiary has turned the corner & is beginning to contribute, profitably. They had the highest of earnings, revenue, this years, sans shennanigans. We may be looking at a company that hits 75 million + in revenue this year & begin to get noticed by the bigger boys.Chuck royce & associates own this also.

So, though I may not be adding anymore, I'd like to retract my harsher comments from earlier last year. I didn't think management would stop doodling around & simply focus on core growth & the rest would follow. But they got it. They finally got it. I hope they continue. While they work on Monovisc, they are doing clinical studies with cingal, which if it works out will be stellar.

I wasn't expecting cost controls, Ankia s.r.l to work out in such fashion. Suffice to say, doubling your eps, sans shennanigans, is a masterful work. Wow, this company may yet turn into a diamond in the rough that I thought it would be 5 years ago.

Only problem, any delays or notifications of delay from FDA crushes the stock, even though it has absolutely no issue from a revenue/ cash flow/ eps metric. So, i gently recant all the stuff I said earlier. i've convinced myself that Anik is a 20-30 dollar stock 3-5 years from now!!!

Recs

1
Member Avatar acts20 (35.41) Submitted: 9/30/2011 10:11:30 AM : Outperform Start Price: $5.41 ANIK Score: +441.68

Ceo sucks. But at low. Buy out prospect. New products

Recs

1
Member Avatar siri22 (< 20) Submitted: 8/31/2011 5:53:55 PM : Outperform Start Price: $6.00 ANIK Score: +390.91

Ceo sucks.....but low end...good products

Recs

1
Member Avatar tunstavurn (< 20) Submitted: 3/2/2011 5:24:57 PM : Underperform Start Price: $9.19 ANIK Score: -207.95

Pending lawsuit with genzyme.
declining margins
Increased competition

Recs

1
Member Avatar Biotechfreak (< 20) Submitted: 2/24/2011 12:09:17 AM : Outperform Start Price: $8.52 ANIK Score: +235.11

Anika Therapeutics has tremendous upside Potential in the near term .

Anika awaiting 4 FDA approvals in the 1H 2011 .The Biotech Company is profitable and cash flow positive .

Anika is definitely one of the best Pick in the Biotech sector .

Recs

0
Member Avatar gsabc (91.68) Submitted: 6/25/2010 9:09:25 AM : Outperform Start Price: $6.16 ANIK Score: +352.65

Small company with very low price-to-book at the moment, but good products , solid revenue stream and great potential growth.

Recs

0
Member Avatar MAD66 (70.45) Submitted: 6/4/2008 12:57:47 PM : Outperform Start Price: $8.81 ANIK Score: +225.15

Good entry point.

Results 1 - 20 of 42 : 1 2 3 Next »

Featured Broker Partners


Advertisement